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Ethical and Policy Issues Raised by Uterus Transplants 
 





Introduction: In 2014, Brännström and colleagues reported the first human live birth following uterine 
transplantation. Research into this treatment for absolute uterine factor infertility has since grown 
with clinical trials currently taking place across centres in Europe, the US and Asia. 
Sources of data: This review summarises and critiques the academic literature on ethical and policy 
issues raised by uterine transplantation. 
Areas of agreement: There is general agreement on the importance of risk reduction and, in principle, 
to the sharing and maintenance of patient data on an international registry. 
Areas of controversy: There are numerous areas of controversy ranging from whether it is ethically 
justified to carry out uterus transplants at all (considering the associated health risks) to how deceased 
donor organs for transplant should be allocated. This review focuses on three key issues: the choice 
between deceased and living donors, ensuring valid consent to the procedure, and access to 
treatment. 
 
Growing points: Uterine transplantation is presently a novel and rare procedure but is likely to 
become more commonplace in the foreseeable future, given the large number of surgical teams 
working on it worldwide. 
 
Areas timely for developing research: Uterus transplantation requires us to re-examine fundamental 
questions about the ethical and social value of gestation.  If eventually extended to transgender 
women or even to men, it may also require us to reconceptualise what it is to be a ‘father’ or to be a 
‘mother’, and the definition of these terms in law. 
 





                                                 
1 The paper was conceived and planned by all three authors.  Initial drafts of the main sections were produced 
by Laura O’Donovan and Nicola Williams.  The whole paper was then edited and revised by all three authors. 
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Ethical and Policy Issues Raised by Uterus Transplants 
Introduction 
Research into uterine transplantation (UTx) dates back to 1960. However, it was not until 2000 that 
the first modern attempt at human uterine transplantation took place, in Saudi Arabia. Though 
unsuccessful, clinical research by various groups gathered pace and, in 2014, Brännström and 
colleagues in Sweden reported the first live birth following living-donor UTx.1 To date, there have been 
11 reported live births following living-donor transplant and one following deceased-donor 
transplant.2 In 2015, the NHS Health Research Authority granted approval for a UK trial study at 
Hammersmith Hospital involving ten patients and brain-stem dead, heart-beating donors.3 More 
recently, in 2018, it was announced that this study would include a further five transplants from living-
donors.4 
Absolute Uterine Factor Infertility (AUFI) is the absence of a functional uterus5 due to congenital 
Müllerian malformations or acquired causes and is described by Brännström as ‘the only major type 
of female infertility still viewed as untreatable’.1 Approximately 1 in 500 women worldwide are 
estimated to have uterine factor infertility,6 with around 15,000 women of childbearing age in the UK 
having no womb.7 The current options for women with AUFI who wish to have children are adoption 
or surrogacy. However, both can be lengthy, bureaucratic and expensive processes and, while 
altruistic surrogacy is legally permitted in the UK, not everyone considers it an acceptable option (for 
cultural, moral, or practical reasons).  UTx, on the other hand, can provide women with the genetic, 
gestational, legal, and social components of motherhood without the need for reliance on a surrogate, 
and also offers the experience of having a child as a result of one’s own pregnancy. 
Uterine transplantation is the world’s first ‘ephemeral’ transplant with most study models 
recommending hysterectomy after a certain period. The treatment finds itself at the cutting edge of 
science, occupying middle ground between innovative transplantation and developments in assisted 
reproductive technology.  Because of this, a wide-ranging ethical and legal literature has arisen in a 
short space of time. The issues it addresses may usefully be categorised into the broad themes of: 
transplantation ethics; donation ethics; questions of access; child welfare; and ethical research design 
and practice. This review explores three particular concerns that have attracted most interest:  the 
value of gestation, the choice between deceased or living donors, and access to treatment.  
 
Areas of agreement in principle 
The risk of physical and psychological complications to recipient, live donor and resulting child have 
occupied a large portion of the literature to date. The first attempted human uterine transplantation 
unfortunately resulted in acute vascular thrombosis requiring removal 99 days after transplantation.8 
Duration of surgery has also been a cause for concern with research ongoing into the use of robotic 
assisted surgery with the aim of reducing the operative time for donors and recipients.9, 10 Further 
physical health risks include post-operative complications such as infection, thrombosis, fistula and 
uretic injury,11 and psychological risks include issues relating to gender identity and sexual 
dysfunction. There are also more general risks such as complications arising from immunosuppressive 
therapy and psychological problems resulting from transplant surgery. Acknowledging this, there is a 
consensus that uterus transplants should not be offered as part of routine clinical practice until safety 
and efficacy are proven.12 More data are required in order fully to understand the risks treatment 
poses and, at this stage, limiting UTx is preferable while ongoing trial outcomes are explored. 
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The second area of agreement in principle concerns the importance of recording and maintaining data 
accumulated as part of registered trials worldwide ‘to further optimize the procedure concerning 
efficiency and safety’.13  The operation of such a registry not only permits data sharing on outcomes 
enabling safety monitoring, but also provides a mechanism through which the practice of uterine 
transplantation can be regulated.14  Although there may be broad consensus that data should be 
shared, the extent of the information included and the principles governing data use (EU countries are 
now subject to General Data Protection Regulations) pose further questions for debate moving 
forward. 
 
The value of gestation 
The value of gestation is a major theme in the ethics literature on UTx. Two main concerns emerge in 
the various discussions: the extent to which UTx serves to reinforce social biases regarding 
reproduction, exacerbating the harm caused by infertility, and whether providing UTx causes 
alternative options to be less acceptable or desirable.  Much criticism of ART (Assisted Reproductive 
Technology) relates to concerns about the ‘motherhood mandate’: an ideology according to which 
motherhood is central to female identity and “having at least two children and raising them well” is a 
norm or requirement for adult women.15 While advances in medicine provide women with more 
reproductive choice, commentators have expressed concerns that increasing options, reflective of 
prevailing social and cultural norms, may intensify both the strength of the desire to procreate using 
ARTs and the harm suffered by individuals who cannot or choose not to do so.16 ARTs (perhaps 
especially UTx) arguably promote a particular kind of family, the biological nuclear family, in which the 
recipient will be both the genetic and gestational mother of any child born. However, a society in 
which biological ties are less valorised may be beneficial and ameliorate some of the harms caused by 
infertility. A related concern is that ARTs, such as UTx, promote and perpetuate the dominance of the 
traditional and/or genetic family described above; this is not an option for some women, their distress 
will be worsened if they are made to feel that surrogacy, adoption or voluntary childlessness are 
inferior alternatives. 16, 17 
 
Living versus Deceased Donation  
Around 75% of uterus transplantation (UTx) procedures (34/45 reported cases) have utilised living 
donors, the majority of which (24/34) have been close relatives of the intended recipients (mothers, 
aunts and sisters) with only 25% (11 reported cases) using uteri from deceased brain-dead donors. As 
with other transplants where both living and deceased donor organs are available, each model comes 
with distinct benefits and challenges. Significant debate has thus arisen about the weight assigned to 
each and thus to the question of which model should be preferred assuming that both are eventually 
proven sufficiently safe and effective. 
 
Clinical and Practical Issues 
One key factor influencing the choice of donor model is the clinical and practical benefits and 
challenges associated with each. Given the relatively small quantity of transplants performed so far, 
and the number of variables influencing success rates, it is difficult to be certain at present about the 
relative merits of each. The deceased donor model for UTx has been associated with several possible 
benefits. These include the ability to retrieve longer lengths of vasculature (which may reduce the risk 
of serious complications for recipients seen in the living donor model such as thrombosis) and a 
simplified transplantation procedure which reduces surgical time and risks of anaesthesia in recipient 
surgeries.18 However, despite such benefits, the majority of physicians trialling UTx hold that - as in 
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other living donation contexts, such as kidney donation and liver lobe donation – the living donor 
model is liable to provide greater benefits. Whether this is the case will become clearer as trials 
progress, but benefits include: closer tissue matching where relatives are used; higher organ quality 
due to significantly lowered warm and cold ischemia times; reduced likelihood of transplanting a 
uterus that is unsuitable for gestation and/or diseased due to the ability to conduct thorough testing 
prior to retrieval absent significant time pressures; the ability more easily to schedule complex 
surgeries including a large team of physicians from different specialties; and reduced waiting times 
resulting from deceased donor organ scarcity. 19 20 
 
Ethical Considerations 
While a concern to maximise success rates and provide practical benefits leads to a preference for 
living donors, a concern for the welfare of and to respect the autonomy of donors tends to pull in the 
opposite direction. In terms of welfare, for example, while the deceased model poses no risks to 
donors, living donation both necessitates and risks serious harms,21, 22 thought to be similar to, or 
slightly greater than, those associated with a total abdominal hysterectomy.23 These are likely to 
diminish over time as surgical techniques and post-operative care are finessed. However, of the cases 
reported so far, four living donors have experienced significant complications requiring surgical, 
endoscopic or radiological intervention under anaesthetic24, 25, 26, 27 and other donors have 
experienced infections, urinary hypotonia, leg and buttock pain, and depression.28 Similarly, concerns 
have also been raised about the welfare of living donors who may end up regretting their choice to 
donate – should, for example, the retrieval/transplant go awry, their relationship with the recipient 
sour, or they find themselves wanting pregnancy later in life – which, again, is avoided in cases where 
deceased donors are used.29 Some commentators however have noted that, while deceased donors 
in UTx are not at risk of harm, their use does pose  risks of harm to third parties in certain contexts. 
Most notable of these is the risk to vital organs (ones which would otherwise be available for 
transplantation) that could occur if uteri were retrieved prior to life-saving organs.30  
 
In terms of respect for autonomy, it could simply be argued that permitting living donation respects 
the autonomy of those who wish to donate by allowing them to do so. However, the position is 
actually more complex. For both living and deceased donation, there is a risk of uteri being obtained 
without sufficiently high-quality consent. For living donation, concerns centre around the possibility 
of living related donors experiencing external pressures such as coercion or manipulation to donate 
from the recipient or other family members,8 and that living unrelated donors may be offered 
incentives (financial or otherwise) which could constitute an autonomy-undermining inducement.31 
The design and implementation of robust consent procedures can reduce such risks, as in other 
donation contexts.  However, some risk will always remain and will be higher in lower income and 
more pro-natalist societies.32 In the context of deceased donation, the unfamiliarity of UTx combined 
with its quality of life enhancing purpose, also poses challenges for obtaining appropriate consent 
from donors and/or their families post-mortem. Given these considerations, consent to donate a 
uterus cannot necessarily be inferred from an individual’s possession of a donor card33 and family 
members may find it difficult to reach an informed decision about the deceased person’s 
preferences.34, 35 However, unlike in the context of living donation, these concerns both pose no threat 
to the psychological welfare of donors and are likely significantly to decrease over time if uterus 
transplantation reaches public consciousness and becomes included in donor registration lists.  
 
A Balancing Act 
Given the risks and harms associated with living donation, a small minority of scholars suggest that – 
as a result of the physician’s duty of non-maleficence and UTx’s status as a quality-of-life, as opposed 
to life-saving, transplant - living donation is inappropriate.  The majority however take a more 
moderate stance suggesting instead that, while harm and risk to donors offer some reason to prefer 
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uteri from deceased donors, this must be balanced against the benefits it offers.36  Thus, as in other 
donation contexts, living donation can be justified provided that: 
 
• Valid and informed consent is given by the donor after mandatory and in-depth counselling 
from donor physicians and psychologists; 
• levels of harm suffered by donors are both proportionate to the benefits produced and fall 
below some accepted threshold; and, 
• attempts are made to minimise the use of living donors and any harms inflicted to them.34 
 
Harm minimisation may be achieved through, for example: 
 
• the promotion of alternatives to transplant such as surrogacy and adoption (where 
permitted);37 
• the use of living donors who have already completed their families/ are undergoing removal 
of healthy uteri as part of a wider gynaecological procedure or gender affirmation surgery;38 
• expansion of the deceased donor pool to include increased/non-standard risk donors;39 
supporting research into future advances in ART which may render the use of living donors 
obsolete such as the bioengineered uterus.34 
 
 
Access to UTx 
Three main issues arise when considering access to uterine transplantation programmes. 
 
(1) Should treatment be publicly funded? 
(2) What selection criteria should be adopted to define the eligible patient base? 
(3) What factors should be incorporated into the allocation ranking system to ensure the 
equitable distribution of non-directed donor uteri? 
 
 
Should treatment be publicly funded? 
 
In the UK, the question of funding this procedure will fall to NHS commissioners once a sufficient 
evidence base has been established. In April 2017, UTx was added to the list of prescribed specialised 
services for which NHS England is the responsible commissioner.40 This avoids clinical commissioning 
groups having to make difficult decisions in respect of local budgets where significant differences in 
the provision of standard treatment for infertility (including IVF and ICSI) exist throughout the UK.41 
 
Ethical opinion on the public funding of UTx is divided. Some critics oppose it altogether citing 
arguments42 relating to the existence and promotion of alternative options (such as surrogacy or 
adoption)16 and questioning the extent to which UTx both responds to, and reinforces, a socially-
conditioned desire to reproduce in a particular way.17, 43 To this end, commentators have argued that 
‘the rhetoric surrounding uterine transplantation points to connections between the ability to 
experience gestation and womanhood or femininity’.17 This may result in devaluing other modes of 
family formation in light of prevailing social biases: pronatalism and geneticism.16, 17 However, these 
arguments also apply to assisted reproduction more generally. For example, the desire to undergo IVF 
in order to have a genetically related child potentially raises the same concerns about pronatalism and 
geneticism and yet publicly funded IVF has not thus far been refused on these grounds. A stronger 
argument against funding can be found in discussions of the risks of treatment to recipient, donor and 
prospective child.44 In this respect, UTx is presently in a weaker position than other ARTs, because it 
has a less well- established track record of safety and efficacy.45  
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Objections to funding UTx have been challenged by various commentators who emphasise the disease 
status of infertility (notwithstanding the possibility that this may be exacerbated by people’s socially 
conditioned desires for particular family forms37, 46) and the difficulty of evaluating the ‘sufficiently 
good alternatives’ to UTx.37 Whether surrogacy or adoption are more or less ‘valuable’ than UTx 
depends in part on the personal preferences of prospective patients.37 Where experiencing gestation 
is significant for the individual concerned and both safety and efficacy of UTx practice are proven, it 
may be the case that public funding is justified in the interests of patient autonomy and wellbeing, if 
the wider social and psychological context is taken into account.47  
 
Selection and allocation criteria  
Uterine transplantation generates particular issues regarding the selection criteria applicable to 
prospective patients and the allocation criteria employed in order to establish a fair system of organ 
distribution. As with other ART services, it seems sensible to employ patient selection criteria in order 
to ensure that only those patients with realistic prospects of success enter treatment. In the context 
of UTx these have included requirements such as: 
 
• being genetically female; 
• being able to provide one’s own oocytes and/or embryos.  
• being able to demonstrate child-rearing capacity; and  
• having appropriate reasons for seeking treatment; 
 
All clinical trials to date have insisted that the organ recipient should be a genetic female with no 
medical contraindications to transplantation.48 For the UK clinical trial, this is expressed as a 
requirement that the recipient has normal ovarian reserve and function.14 It has been suggested that 
there may be a case for eventually providing UTx to transgender women, enabling the alignment of 
reproductive capabilities with acquired gender identity.49 However, due to anatomical and 
physiological differences between chromosomally male and female bodies, further scientific research 
is required in order to demonstrate feasibility50 and, as such, the exclusion of chromosomally male 
recipients from UTx trials seems justified for the time being. 
 
Criteria relating to child-rearing capacity are also contentious. Commentators have argued that, given 
that the purpose of UTx is childbirth, recipients should be required to meet certain quality thresholds 
for child-rearing.34, 51  Criminal background checks, as well as financial and socio-psychological 
evaluations have been proposed to assess comprehensively parenting ability.34 In the UK, this is 
encapsulated to a less invasive extent in the ‘welfare of the child’ assessment required by the Human 
Fertilisation and Embryology Act 1990 (as amended) prior to the provision of any treatment services. 
This applies to all fertility treatment regulated by the Human Fertilisation and Embryology Authority 
and as such is better understood as a threshold selection requirement. Clinicians must take account 
of the welfare of any child who may be born as a result of the treatment (including the need of that 
child for supportive parenting) and of any other child who may be affected by the birth.52 Common 
considerations include: ‘any aspects of the patient’s (or their partner’s) (a) past or current 
circumstances that may lead to any child experiencing serious physical or psychological harm, or 
neglect, or, (b) circumstances that are likely to lead to an inability to care throughout childhood for 
any child born as a result of treatment, or that are already seriously impairing the care of an existing 
child of the family’.53 While consideration of the welfare of the future child in ART treatment is 
accepted (though not without controversy54), commentators have been careful to warn against biased 
social value judgments, particularly regarding questions as to what might constitute a ‘good mother’34, 
in order to avoid unfair discrimination between prospective patients.  
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Consideration of patients’ reasons for seeking treatment is relatively uncontroversial; it is generally 
agreed that treatment should only be provided to those seeking UTx in order to reproduce and 




Similar discussions have arisen about equitable organ allocation policy. Not only is UTx a quality of life 
enhancing as opposed to life-saving transplant, it also presents distinct and complex allocation 
challenges. In part, this is because AUFI in particular does not come in degrees (because all those with 
it have an equal chance, i.e. no chance, of reproducing ‘naturally’).  Therefore, factors additional to 
ones traditionally applied in the context of other composite tissue allografts (assessing clinical health 
status) are required to ensure the fair allocation of non-directed donor uteri. Due to the stated goal 
and purpose of UTx, social factors will be important in any proposed patient ranking system. To this 
end, commentators34, 51 have suggested criteria based on a variety of psychosocial and medical factors, 
such as: 
• presence of existing children, especially where these are biologically related to the 
prospective recipient; 
• amount (and cost) of infertility treatment required; 
• priority for those for whom it is hard to find a suitable donor (e.g. highly sensitised groups, 
those with high antibody levels, members of some ethnic minority groups); 
• age of the recipient. 
 
Regarding the presence of existing children, it has been suggested that women who have already 
experienced gestation and birth or, more strongly, are already genetic and/or social parents should 
receive lower priority.34, 51 In publicly funded healthcare systems, the presence of an existing child of 
the patient or of the family is sometimes utilised (for example, by Clinical Commissioning Groups in 
England) as a threshold criterion to limit access to available services.41 Given finite resources, this kind 
of ranking may be justified in order to ensure fair treatment distribution.34 However, any proposal to 
limit access to those who have not experienced gestation is liable to prove controversial. 
As a criterion to assist with patient ranking, the amount of infertility treatment required is currently 
of limited assistance. All patients will require IVF given that the uterine graft is not connected to the 
patient’s fallopian tubes, and that therefore natural pregnancy is not possible. However, if further 
clinical research enables natural pregnancy following UTx in future, prioritising women requiring 
transplant only could potentially be justified on cost-effectiveness grounds.51 Further, prioritising 
those who are members of highly sensitised groups due to difficulties associated with finding suitable 
tissue matches is uncontroversial. This is routinely considered in the allocation of solid-organ 
transplants where it does not prejudice severely ill patients, and should similarly apply to UTx. 
Ranking criteria based on the age of the recipient also provide an interesting area for discussion. The 
purpose of uterine transplantation is to provide or restore reproductive capacity to women with AUFI. 
Reproductive function naturally declines with age and so it is argued that ranking policies ought to 
mimic the natural reproductive lifecycle and seek to admit only those women falling within an ‘age-
relative opportunity range’.51 Views on what constitutes normal childbearing age will vary between 
countries and, due to differing social norms and practices, this may be an area where it is difficult to 
reach international agreement. In the US literature, account has been taken of definitions advanced 
by the World Health Organisation, assessment of the medical literature on advanced maternal 
pregnancy and egg donation, and consideration of the hardships of teen pregnancy, resulting in a 
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proposed range of between 20 and 45 years. In publicly-funded systems like the NHS, it is important 
to ensure equality between the different assisted conception treatments, particularly given that UTx 
patients also require standard IVF. Guidelines from the National Institute of Health and Care 
Excellence state that women up to age 40 should be offered three full cycles of IVF, while women aged 
40-42 years should be offered one. This suggests an upper age limit of 42 for UTx in the UK, though 
current recipient inclusion criteria in the UK clinical trial mandates an age range of 24-38 (40 if embryos 
frozen < 38 years).14 Further account then ought to be taken of where women fall within this 
established age-range. It has been suggested that those nearing the upper limit ought to be afforded 
additional priority on the basis of their retreating opportunity to have children. 51, 34 It has also been 
suggested that time on the waiting list should be considered.51, 34 How much weight this should be 
accorded in the ranking process is a question that requires further work, especially considering the 
fact that women with AUFI due to congenital abnormality will be able to seek to join the waiting list 
from the lower age limit. 
 
The Way Forward 
Uterus transplantation raises important ethical, social, and regulatory questions. Some of these result 
from, or at least are exacerbated by, the experimental status of UTx.  For these, answers or solutions 
are likely to emerge over the short- to medium-term as better data about the benefits and risks of UTx 
emerge, and policy is amended in the light of these. This applies in particular to issues such as whether 
to use living or deceased donors; the welfare of children born through UTx; whether UTx meets 
funding thresholds; UTx in transgender populations; and allocation criteria for recipients. 
However, uterus transplantation also forces re-examination of more foundational questions, ones 
that cannot be fully answered by trial data. These are ultimately questions of axiology, of what we do 
and should value, and how we should respond to that value individually and as a society. Such 
questions include but are not limited to – 
• What value should we ascribe to gestation and to enabling people to carry their own future 
children within the womb? 
• What responsibilities as a society do we have to alleviate the social and psychological harms 
caused by infertility? 
• What are the proper limits of medicine? 
• What levels of risk to donors and recipients are acceptable for quality of life enhancing (as 
opposed to life-prolonging) transplantations? 
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